Palmar Hyperhidrosis - Pipeline Insight, 2022

DelveInsight’s, “Palmar Hyperhidrosis- Pipeline Insight, 2022,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Palmar Hyperhidrosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Global coverage
Palmar Hyperhidrosis Understanding

Palmar Hyperhidrosis: Overview
Palmar hyperhidrosis, or excessive hand sweating, is a common condition affecting 1-3% of the population. It usually starts in childhood or adolescence. Sweaty hands can significantly affect a person socially and emotionally. Many factors can contribute to the condition, including genetic influences as well as physical and emotional stress. A family history is present in up to 30% of cases. Palmar hyperhidrosis affects both hands equally and can range from mild clammy hands to severe sweating. It stops when sleep. Sweaty hands can be associated with increased sweating in other parts of the body including underarms (axillary hyperhidrosis), face and scalp (craniofacial hyperhidrosis) and feet (plantar hyperhidrosis).The condition can be very distressing due to its impact on quality of life. The diagnosis is usually made based on a history of excessive sweating. No investigations are needed. Further investigations are considered when larger areas of the body are affected or if hyperhidrosis occurs during sleep. Palmar hyperhidrosis will often need ongoing and persistent treatment. However, some people may notice the amount of sweating decreases as they get older. There seems to be a genetic predisposition to PH, evidenced by family transmission through autosomal dominant genes. Symptoms are usually bilateral and symmetrical and there are no other associated conditions. Palms are cold, wet and present color that can ranges from pale to blush. The episode of sweating has abrupt onset, related or not with emotional stressful events, and presents more intensely on the palms and fingers and less intensely in the posterior regions of the hands. Rapidly, the hands are wet by the droplet detachment, and in some cases there may be swelling of the fingers. The PH diagnosis is eminently clinical, being conducted through history and physical examination.

""Palmar Hyperhidrosis- Pipeline Insight, 2022"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Palmar Hyperhidrosis pipeline landscape is provided which includes the disease overview and Palmar Hyperhidrosis treatment guidelines. The assessment part of the report embraces, in depth Palmar Hyperhidrosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Palmar Hyperhidrosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Palmar Hyperhidrosis R&D. The therapies under development are focused on novel approaches to treat/improve Palmar Hyperhidrosis.

Palmar Hyperhidrosis Emerging Drugs Chapters
This segment of the Palmar Hyperhidrosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Palmar Hyperhidrosis Emerging Drugs
AT-5214: Atacama Therapeutics
AT-5214 (dexmecamylamine) is the S-enantiomer of mecamylamine, a selective inhibitor of the acetylcholine nicotinic receptor. AT-5214 is thought to inhibit the sympathetic ganglion with lessened parasympathetic side effects. Currently, it is in Phase II stage of development to treat Palmar Hyperhidrosis.
Umeclidinium: GlaxoSmithKline
Umeclidinium is a Muscarinic receptor antagonist developed by GlaxoSmithKline. It is in Phase II stage of development to treat Palmar Hyperhidrosis.
Further product details are provided in the report……..

Palmar Hyperhidrosis: Therapeutic Assessment
This segment of the report provides insights about the different Palmar Hyperhidrosis drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Palmar Hyperhidrosis
There are approx. 3+ key companies which are developing the therapies for Palmar Hyperhidrosis. The companies which have their Palmar Hyperhidrosis drug candidates in the most advanced stage, i.e. phase II include, Atacama Therapeutics.
Phases
DelveInsight’s report covers around 3+ products under different phases of clinical development like
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Palmar Hyperhidrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Intra-articular
Intraocular
Intrathecal
Intravenous
Ophthalmic
Oral
Parenteral
Subcutaneous
Topical
Transdermal
Molecule Type

Products have been categorized under various Molecule types such as
Oligonucleotide
Peptide
Small molecule
Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Palmar Hyperhidrosis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Palmar Hyperhidrosis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Palmar Hyperhidrosis drugs.

Palmar Hyperhidrosis Report Insights
Palmar Hyperhidrosis Pipeline Analysis
Therapeutic Assessment
Unmet Needs
Impact of Drugs
Palmar Hyperhidrosis Report Assessment
Pipeline Product Profiles
Therapeutic Assessment
Pipeline Assessment
Inactive drugs assessment
Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
How many companies are developing Palmar Hyperhidrosis drugs?
How many Palmar Hyperhidrosis drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Palmar Hyperhidrosis?
What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Palmar Hyperhidrosis therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Palmar Hyperhidrosis and their status?
What are the key designations that have been granted to the emerging drugs?

Key Players
Atacama Therapeutics
GlaxoSmithKline
Brickell Biotech, Inc.
Candesant Biomedical

Key Products
AT-5214
Umeclidinium
Sofpironium bromide